About the Research Roundtable
The mission of the Alzheimer's Association Research Roundtable (AARR) is to advance the research, development and management of new treatments for Alzheimer’s disease.
The AARR is a consortium of senior scientists from the pharmaceutical, biotechnology, diagnostics, imaging and cognitive testing industries, and senior staff and advisors from the Association. Begun in 2003 with four members, the Research Roundtable now includes more than 20 corporate members, whose scientists participate in the Roundtable to contribute to and benefit from the state-of-the-field scientific discourse, debate, and information sharing in order to advance the field of Alzheimer’s research and development. Additional participants include invited investigators from academia and such international government organizations as the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and the National Institutes of Health.
Through the Research Roundtable, the Alzheimer's Association brings together industry leaders with top scientists from around the world to discuss key areas in Alzheimer's science in a precompetitive platform. The Roundtable convenes twice each year for coverage of topics identified by Roundtable members as the most current critical needs. The Roundtable may also focus on specific issues facing the AD field that impact many of the member companies by forming a Task Force or Work Group.
Roundtable members explore a broad range of Alzheimer's cutting edge science topics, including:
- New data and technologies that may improve the diagnosis of Alzheimer's disease, especially in its earliest and mildest stages.
- Neuropsychological testing, genetic factors, and biochemical and neuroimaging biomarkers that could contribute to an earlier and more accurate Alzheimer's diagnosis.
- Lessons learned about clinical trial design that may help shape future clinical trials of drugs aimed at slowing or stopping the progression of Alzheimer's.
- The pros and cons of various scales as outcomes measures of clinical trials.
The outputs of Roundtable meetings are published as articles in the Alzheimer's Association's journal, Alzheimer's & Dementia® and have had major impacts in the field of Alzheimer’s disease. For example, the NIA/AA diagnostic criteria for Alzheimer's disease published in 2011 were first highlighted as needed in the field at an AARR meeting.
Back to top
Current 2016 members
The Research Roundtable also sponsors Alzheimer's Association grants. The chosen project is named Research Roundtable Sponsored Grant and the principal investigator of the project is invited to give a progress report at a Roundtable meeting.
The Dale Schenk Alzheimer's Association Research Roundtable Grant Award
2016 Dale Schenk Alzheimer's Association Research Roundtable Grant Awardees
Investigating a Frameshift Deletion in ABCA7 of African Origin Using iPSC
University of Miami
Annina Maria DeLeo
Characterization of Human Alzheimer’s Disease Brain-Derived Exosomes on Tau Propagation
Boston University Medical Campus
Visit our Grants page
to learn more about Association research funding.
Back to top
Join the Research Roundtable
We invite companies to join the thought leaders in Alzheimer's research at the
Research Roundtable. Sponsorship terms are for 12 months beginning on the date of a signed agreement.
For more information, please contact: Jay Thompson, Senior Associate Director
Corporate Initiatives at 312.335.5192 or email@example.com.